Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268324 | 1.00 | KCNH2 (0.36) | KCNH2LMNATHRBHASPIN | |
| SCHEMBL23268395 | 0.81 | KCNH2 (0.38) | KCNH2LMNATHRBHASPIN | |
| SCHEMBL23268405 | 0.77 | RET (0.33) | KCNH2LMNATHRB | |
| SCHEMBL23268357 | 0.77 | RET (0.33) | KCNH2LMNATHRB | |
| SCHEMBL23288661 | 0.76 | LMNA (0.31) | KCNH2LMNATHRB | |
| SCHEMBL23268382 | 0.76 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL23244824 | 0.75 | KCNH2 (0.57) | KCNH2HASPIN | |
| SCHEMBL23288616 | 0.72 | KCNH2 (0.45) | KCNH2LMNATHRBHASPIN | |
| SCHEMBL23288642 | 0.71 | LMNA (0.31) | LMNATHRB | |
| SCHEMBL23268258 | 0.71 | KCNH2 (0.30) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | KCNH2 434/4885LMNA 1146/4885THRB 4546/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | KCNH2 434/4885LMNA 1146/4885THRB 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.